

Gad Singer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1480785/publications.pdf>

Version: 2024-02-01

60
papers

3,360
citations

331670

21
h-index

144013

57
g-index

62
all docs

62
docs citations

62
times ranked

3448
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT [®] Bladder Cancer Monitor and Narrow Band Imaging [®] Cystoscopy. <i>Cancers</i> , 2022, 14, 618.	3.7	7
2	High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy. <i>BMC Cancer</i> , 2022, 22, 376.	2.6	4
3	Deciphering the genetic landscape of pulmonary lymphomas. <i>Modern Pathology</i> , 2021, 34, 371-379.	5.5	2
4	Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix. <i>Diagnostics</i> , 2021, 11, 623.	2.6	1
5	High Density of CD16+ Tumor-Infiltrating Immune Cells in Recurrent Ovarian Cancer Is Associated with Enhanced Responsiveness to Chemotherapy and Prolonged Overall Survival. <i>Cancers</i> , 2021, 13, 5783.	3.7	3
6	Interobserver variability and likelihood of malignancy for fifth edition BI-RADS MRI descriptors in non-mass breast lesions. <i>European Radiology</i> , 2020, 30, 77-86.	4.5	32
7	Towards clinical grating-interferometry mammography. <i>European Radiology</i> , 2020, 30, 1419-1425.	4.5	43
8	Stereotactic Vacuum-Assisted Breast Biopsy in Ductal Carcinoma in situ: Residual Microcalcifications and Intraoperative Findings. <i>Breast Care</i> , 2020, 15, 386-391.	1.4	6
9	High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 127-136.	2.5	20
10	Viropathic multinuclear syncytial giant cells in bronchial fluid from a patient with COVID-19. <i>Journal of Clinical Pathology</i> , 2020, 73, 607-608.	2.0	12
11	Can grating interferometry-based mammography discriminate benign from malignant microcalcifications in fresh biopsy samples?. <i>European Journal of Radiology</i> , 2020, 129, 109077.	2.6	5
12	ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceded by clonally related lymphomatoid papulosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 763-767.	2.8	9
13	PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 67-76.	2.8	13
14	High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy. <i>BMC Cancer</i> , 2018, 18, 425.	2.6	24
15	MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity. <i>BMC Cancer</i> , 2016, 16, 639.	2.6	13
16	Correspondence: Reply to "Quantitative evaluation of X-ray dark-field images for microcalcification analysis in mammography" [™] . <i>Nature Communications</i> , 2016, 7, 10868.	12.8	8
17	Epidemiology in ovarian carcinoma: Lessons from autopsies. <i>Gynecologic Oncology</i> , 2015, 138, 417-420.	1.4	5
18	Non-invasive classification of microcalcifications with phase-contrast X-ray mammography. <i>Nature Communications</i> , 2014, 5, 3797.	12.8	110

#	ARTICLE	IF	CITATIONS
19	A Study on Mastectomy Samples to Evaluate Breast Imaging Quality and Potential Clinical Relevance of Differential Phase Contrast Mammography. <i>Investigative Radiology</i> , 2014, 49, 131-137.	6.2	57
20	Bone Marrow Micrometastases Do Not Impact Disease-Free and Overall Survival in Early Stage Sentinel Lymph Node–Negative Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2014, 21, 401-407.	1.5	6
21	Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 565-574.	2.8	13
22	High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1295-1302.	2.5	23
23	Phase-contrast enhanced mammography: A new diagnostic tool for breast imaging. , 2012, , .		0
24	Breast Abscesses: Diagnosis, Treatment and Outcome. <i>Breast Care</i> , 2012, 7, 32-38.	1.4	25
25	Board examination for anatomical pathology in Switzerland: two intense days to verify professional competence. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 87-92.	2.8	4
26	How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists. <i>PLoS ONE</i> , 2012, 7, e37379.	2.5	175
27	Histopathologic characteristics of the transitional stage of measles-associated appendicitis: case report and review of the literature. <i>Human Pathology</i> , 2011, 42, 285-290.	2.0	9
28	The First Analysis and Clinical Evaluation of Native Breast Tissue Using Differential Phase-Contrast Mammography. <i>Investigative Radiology</i> , 2011, 46, 801-806.	6.2	228
29	Indeterminate adnexal masses at ultrasound: effect of MRI imaging findings on diagnostic thinking and therapeutic decisions. <i>European Radiology</i> , 2011, 21, 1301-1310.	4.5	35
30	Breast cancer with non-inflammatory skin involvement: Current data on an underreported entity and its problematic classification. <i>Breast</i> , 2010, 19, 59-64.	2.2	12
31	Three-dimensional pathological size assessment in primary breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 257-262.	2.5	7
32	Pathology of Breast Tissue Obtained in Minimally Invasive Biopsy Procedures. <i>Recent Results in Cancer Research</i> , 2009, 173, 137-147.	1.8	2
33	ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 252-253.	1.4	14
34	Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 52-57.	1.7	31
35	Glypican-3 Expression in Primary and Recurrent Ovarian Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 341-344.	1.4	61
36	Retroperitoneal displacement of ovary and fallopian tube: a complication of surgical management of incarcerated inguinal hernia in female infants. <i>Journal of Pediatric Surgery</i> , 2007, 42, e33-e35.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Metastatic patterns at autopsy in patients with ovarian carcinoma. <i>Cancer</i> , 2007, 110, 1272-1280.	4.1	61
38	Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features. <i>Journal of Surgical Oncology</i> , 2007, 95, 291-297.	1.7	11
39	T4 breast cancer under closer inspection: A case for revision of the TNM classification. <i>Breast</i> , 2007, 16, 625-636.	2.2	16
40	Association of the Presence of Bone Marrow Micrometastases with the Sentinel Lymph Node Status in 410 Early Stage Breast Cancer Patients: Results of the Swiss Multicenter Study. <i>Annals of Surgical Oncology</i> , 2007, 14, 1896-1903.	1.5	14
41	Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. <i>Breast Cancer Research</i> , 2006, 8, R51.	5.0	15
42	Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b). <i>Human Pathology</i> , 2006, 37, 264-271.	2.0	12
43	Epithelial growth factor receptor status in primary and recurrent ovarian cancer. <i>Modern Pathology</i> , 2006, 19, 607-610.	5.5	71
44	T4 category revision enhances the accuracy and significance of stage III breast cancer. <i>Cancer</i> , 2006, 106, 2569-2575.	4.1	10
45	A new approach in breast cancer with non-inflammatory skin involvement. <i>Acta Oncologica</i> , 2006, 45, 576-583.	1.8	21
46	Expression of peroxisome proliferator activated receptor α and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. <i>Journal of Clinical Pathology</i> , 2006, 60, 307-310.	2.0	15
47	11 CDX2 Immunostaining in Primary and Secondary Ovarian Carcinomas. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, 4, 393-397.	0.0	0
48	Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis. <i>American Journal of Surgical Pathology</i> , 2005, 29, 218-224.	3.7	388
49	Breast carcinoma with noninflammatory skin involvement (T4b). <i>Cancer</i> , 2005, 104, 1862-1870.	4.1	19
50	Placental site trophoblastic tumor of the mediastinum. <i>Human Pathology</i> , 2005, 36, 581-584.	2.0	13
51	Different types of microsatellite instability in ovarian carcinoma. <i>International Journal of Cancer</i> , 2004, 112, 643-646.	5.1	60
52	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 484-486.	6.3	762
53	KIT in Ovarian Carcinoma: Disillusion About a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1009-1010.	6.3	9
54	Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor). <i>International Journal of Gynecological Pathology</i> , 2003, 22, 37-41.	1.4	116

#	ARTICLE	IF	CITATIONS
55	HLA-G is a potential tumor marker in malignant ascites. <i>Clinical Cancer Research</i> , 2003, 9, 4460-4.	7.0	141
56	Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1697-1703.	6.3	119
57	HLA-G Immunoreactivity Is Specific for Intermediate Trophoblast in Gestational Trophoblastic Disease and Can Serve as a Useful Marker in Differential Diagnosis. <i>American Journal of Surgical Pathology</i> , 2002, 26, 914-920.	3.7	125
58	Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma. <i>American Journal of Pathology</i> , 2002, 160, 1223-1228.	3.8	320
59	Letter to the editors. <i>Surgery</i> , 2002, 131, 473.	1.9	1
60	Transitional cell carcinoma of the vagina with pagetoid spread pattern. <i>Human Pathology</i> , 1998, 29, 299-301.	2.0	20